LONDON, UK - Imperial College-based biotech startup Baseimmune has secured USD4.8m funding to develop the next generation of future-proof universal vaccines against major human and animal diseases.
Around 1.5 million people die every year around the world due to a lack of effective vaccines.* There is an urgent need to develop better universal vaccines against existing diseases, including, COVID, flu and malaria, as well as future-proof vaccines that can cope with the emergence of new threats and variants.
*It’s all about the antigen*
Vaccines work by training the immune system to recognise and respond to infection with a specific pathogen, such as a virus, parasite or bacteria. At the heart of every vaccine is an antigen - a small, safe molecule based on part of the pathogen, which triggers the protective immune response.
Most vaccine antigens are based on a single pathogen component, such as the spike protein of the COVID...